ORTHO-NOVUM 1/50 21 Drug Patent Profile

When do Ortho-novum 1/50 21 patents expire, and what generic alternatives are available?

Ortho-novum 1/50 21 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.

The generic ingredient in ORTHO-NOVUM 1/50 21 is mestranol; norethindrone. There are eleven drug master file entries for this compound. Additional details are available on the mestranol; norethindrone profile page.

Summary for ORTHO-NOVUM 1/50 21

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORTHO-NOVUM 1/50 21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Pharm	ORTHO-NOVUM 1/50 21	mestranol; norethindrone	TABLET;ORAL-21	012728-004	Approved Prior to Jan 1, 1982		DISCN	No	No

ORTHO-NOVUM 1/50 21: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

This report analyzes the investment potential of ORTHO-NOVUM 1/50 21, a combined oral contraceptive. The analysis covers its patent landscape, market positioning, competitive environment, and regulatory status. Key considerations for investors include patent expiry, market penetration, and the introduction of new contraceptive technologies.

What is the Patent Status of ORTHO-NOVUM 1/50 21?

ORTHO-NOVUM 1/50 21, a product of Ortho Pharmaceutical Corporation (now part of Johnson & Johnson), utilizes a combination of ethinyl estradiol and norethindrone. The original patents covering these active pharmaceutical ingredients (APIs) and their contraceptive formulations have long expired.

• Active Ingredients:
  • Ethinyl estradiol: Patented by the Upjohn Company, with original patents expiring in the mid-1960s.
  • Norethindrone: Patented by Parke-Davis (now part of Pfizer), with original patents expiring in the late 1960s/early 1970s.
• Formulation Patents: Ortho Pharmaceutical Corporation held numerous patents related to the specific formulations and packaging of ORTHO-NOVUM 1/50 21. These patents also have expired. For example, U.S. Patent 3,551,618, covering a specific tablet formulation, expired in 1988 [1].

The absence of active patent protection means that ORTHO-NOVUM 1/50 21 is a fully genericized product. This allows for multiple manufacturers to produce and market bioequivalent versions, significantly impacting pricing and market share dynamics.

What is the Market Positioning and Competitive Landscape for ORTHO-NOVUM 1/50 21?

ORTHO-NOVUM 1/50 21 was once a leading brand in the oral contraceptive market. Its market positioning was based on:

• Established Efficacy: A proven track record of preventing pregnancy with consistent use.
• Dosage Strength: The 1/50 formulation (1 mg norethindrone and 50 mcg ethinyl estradiol) was a common and effective dosage in its class.
• Brand Recognition: Decades of marketing and physician recommendation fostered strong brand loyalty among healthcare providers and patients.

The competitive landscape for ORTHO-NOVUM 1/50 21 has evolved significantly:

• Generic Competition: The expiration of patents has led to widespread generic availability. Numerous companies offer generic versions of ethinyl estradiol/norethindrone 1mg/50mcg pills, often at substantially lower prices than the branded product.
• Lower-Dose Alternatives: The pharmaceutical industry has developed and widely adopted lower-dose oral contraceptives. These aim to reduce the risk of estrogen-related side effects, such as thromboembolic events. Examples include products with 30 mcg, 20 mcg, or even 10 mcg of ethinyl estradiol. These lower-dose formulations have captured a significant portion of the market.
• Newer Contraceptive Technologies: The market now includes a wide array of contraceptive methods beyond oral pills, including:
  • Vaginal rings (e.g., NuvaRing)
  • Transdermal patches (e.g., Xulane)
  • Intrauterine devices (IUDs), both hormonal and non-hormonal
  • Injectable contraceptives
  • Implantable contraceptives (e.g., Nexplanon)

These newer methods offer different benefits, such as extended duration of action, reduced user burden (less frequent dosing), and sometimes different risk profiles, all contributing to a fragmented and highly competitive market.

Market Share and Sales Trends

Data on the specific sales of branded ORTHO-NOVUM 1/50 21 is difficult to isolate due to its integration into Johnson & Johnson's broader pharmaceutical portfolio and the dominance of generic alternatives. However, the overall market for ethinyl estradiol/norethindrone 1mg/50mcg products has likely seen a decline in volume and value share for the original branded product as generics and lower-dose options have gained traction.

• Volume: While generic versions maintain a presence, the volume of prescriptions for the higher 50 mcg ethinyl estradiol formulation is generally lower than for newer, lower-dose products.
• Value: The value of the branded product is severely eroded by generic competition and the availability of lower-cost alternatives. The market value is now largely driven by generic sales and the higher price points of newer, more advanced contraceptive technologies.

The American College of Obstetricians and Gynecologists (ACOG) guidelines and clinical practice have shifted towards recommending lower-dose estrogen preparations unless specific clinical indications necessitate higher doses [2]. This trend further disadvantages higher-dose formulations like ORTHO-NOVUM 1/50 21.

What is the Regulatory Status and Manufacturing Considerations?

ORTHO-NOVUM 1/50 21, as an established oral contraceptive, is regulated by health authorities such as the U.S. Food and Drug Administration (FDA).

• FDA Approval: The drug has been approved by the FDA for marketing in the United States for many years.
• Manufacturing Standards: Manufacturers of both the branded and generic versions must adhere to Current Good Manufacturing Practices (cGMP) as stipulated by the FDA. This ensures product quality, safety, and efficacy.
• Labeling and Prescribing Information: Labeling must comply with FDA requirements, including warnings, contraindications, adverse reactions, and efficacy data. The prescribing information for ethinyl estradiol/norethindrone 1mg/50mcg reflects the known risks associated with combined oral contraceptives, particularly the increased risk of serious cardiovascular events in users aged 35 and older who smoke, and the general risk of venous thromboembolism [3].

Manufacturing Considerations:

• API Sourcing: Manufacturers rely on suppliers of ethinyl estradiol and norethindrone APIs. The quality and consistency of these APIs are critical.
• Formulation and Production: The formulation requires precise blending of APIs with excipients and compression into tablets. The 21-day regimen requires specific packaging.
• Quality Control: Rigorous quality control testing is essential at all stages of production to ensure tablet potency, uniformity, and dissolution.
• Cost of Goods: For generic manufacturers, efficient manufacturing processes and cost-effective API sourcing are paramount to competing on price.

Johnson & Johnson continues to market ORTHO-NOVUM 1/50 21 under its brand name, but the volume is likely limited, serving a niche of patients or physicians who prefer the established brand and formulation.

What are the Key Growth Drivers and Restraints for ORTHO-NOVUM 1/50 21?

Given its mature product status and the market dynamics, ORTHO-NOVUM 1/50 21 faces limited growth drivers and significant restraints.

Growth Drivers (Limited):

• Physician Preference/Habit: A small segment of healthcare providers may continue to prescribe ORTHO-NOVUM 1/50 21 based on long-standing familiarity and perceived efficacy, particularly for patients who have used it successfully without issues for years.
• Patient Loyalty: Some patients who have used the drug for an extended period without experiencing side effects may wish to continue with a familiar and effective method.
• Cost-Effectiveness (Generic): Generic versions are highly cost-effective, making them accessible to a broad patient population, especially in markets with limited insurance coverage.

Restraints:

• Patent Expiry and Genericization: The fundamental restraint is the complete absence of patent protection, leading to intense price competition.
• Shift to Lower-Dose Formulations: The established trend towards lower-estrogen doses to mitigate side effects is a primary driver for the decline of 50 mcg ethinyl estradiol products.
• Competition from Newer Contraceptive Methods: The availability of IUDs, implants, patches, and rings offers superior convenience, longer duration of action, and in some cases, different risk-benefit profiles, diverting market share from traditional oral contraceptives.
• Side Effect Profile: The higher estrogen dose carries a greater risk of certain side effects, such as venous thromboembolism, compared to lower-dose options.
• User Compliance: Like all oral contraceptives, efficacy is highly dependent on correct and consistent daily use. Newer methods with longer action can overcome adherence issues.
• Market Maturity: The oral contraceptive market, as a whole, is mature. Growth in this category is now largely driven by innovation in new delivery systems and formulations rather than increases in the basic pill market.

What is the Financial Outlook and Investment Potential?

The financial outlook for branded ORTHO-NOVUM 1/50 21 is likely characterized by declining sales volume and revenue. The primary value in this product now resides with its generic equivalents.

Branded Product (Ortho Pharmaceutical/J&J):

• Revenue: Expected to be stable to declining. Sales will be driven by legacy prescriptions and potentially some residual brand loyalty.
• Profitability: Margins will be pressured by marketing costs to maintain brand awareness against generics and the overall market shift.
• Investment Potential: Low. The product is a mature, genericized asset with minimal growth prospects. Its value to J&J is largely as part of a comprehensive women's health portfolio, rather than a standalone growth engine.

Generic Versions:

• Revenue: Dependent on market share and pricing. The market is highly competitive, leading to price erosion.
• Profitability: Driven by efficient manufacturing and cost control. Margins are typically lower than for branded products but can be stable if production costs are managed effectively.
• Investment Potential: Moderate for generic manufacturers with strong operational capabilities. The market for generic ethinyl estradiol/norethindrone is established and will continue to exist, but significant returns will be difficult to achieve due to intense competition. Investment in generic pharmaceuticals is often about volume and efficiency rather than innovation.

Overall Investment Scenario:

Investing directly in ORTHO-NOVUM 1/50 21 as a branded product offers limited upside. The company that currently markets the branded product (Johnson & Johnson) benefits from the product's legacy and its contribution to a broader portfolio.

For investors seeking opportunities in the contraceptive space, the focus should be on:

1. Companies developing novel contraceptive technologies: This involves higher risk but potentially higher reward.
2. Leading generic manufacturers: These companies can achieve stable revenues by efficiently producing and distributing high-volume generic drugs like ethinyl estradiol/norethindrone.
3. Products with remaining patent protection or strong differentiation: Investing in products with ongoing patent exclusivity or those that represent a significant therapeutic advancement offers a clearer path to growth.

The investment scenario for ORTHO-NOVUM 1/50 21 itself is one of a mature, commoditized product. Its primary relevance is as a benchmark for established oral contraceptive efficacy and as a component of the historical development of the women's health market.

Key Takeaways

• ORTHO-NOVUM 1/50 21's active pharmaceutical ingredient and formulation patents have expired, rendering it a fully genericized product.
• The market has shifted significantly towards lower-dose oral contraceptives and newer, more convenient contraceptive technologies (IUDs, implants, patches, rings).
• The higher estrogen dose (50 mcg ethinyl estradiol) in ORTHO-NOVUM 1/50 21 is associated with increased risks compared to modern lower-dose alternatives.
• While generic versions of ethinyl estradiol/norethindrone 1mg/50mcg remain available, the branded product faces declining market share and limited growth prospects.
• Investment potential in the branded ORTHO-NOVUM 1/50 21 is low, with value now residing in cost-efficient generic manufacturing.

Frequently Asked Questions

1. Will Ortho Pharmaceutical re-patent ORTHO-NOVUM 1/50 21? No, the fundamental patents for the active ingredients and early formulations have long expired and cannot be re-patented. New patents might cover novel delivery systems or specific manufacturing processes, but not the core drug.
2. What is the primary reason for the decline in the use of 50 mcg ethinyl estradiol pills? The primary reason is the recognition of increased risks of adverse cardiovascular events, particularly venous thromboembolism, with higher estrogen doses compared to lower-dose alternatives.
3. Are there any clinical advantages of ORTHO-NOVUM 1/50 21 over newer contraceptives? For a small subset of patients, higher doses may provide more predictable cycle control or may be necessary if lower doses prove ineffective for menstrual regulation. However, for primary contraception, newer methods often offer advantages in convenience and adherence.
4. How does the pricing of generic ORTHO-NOVUM 1/50 21 compare to branded versions of newer contraceptives like IUDs? Generic ORTHO-NOVUM 1/50 21 is significantly less expensive on a per-cycle basis than most branded newer contraceptive technologies. However, the total cost of ownership for IUDs or implants can be lower over their multi-year lifespan.
5. What regulatory hurdles would a new manufacturer face in producing a generic version of ORTHO-NOVUM 1/50 21? A new manufacturer must demonstrate bioequivalence to the reference listed drug (which could be the original branded ORTHO-NOVUM 1/50 21 or another FDA-approved equivalent) through an Abbreviated New Drug Application (ANDA). They must also adhere to FDA's cGMP standards for manufacturing and quality control.

Citations

[1] U.S. Patent 3,551,618. (1971). Ortho Pharmaceutical Corporation. [2] American College of Obstetricians and Gynecologists. (2017). ACOG Practice Bulletin No. 186: Combined Hormonal Contraceptives. Obstetrics & Gynecology, 130(1), e47-e57. [3] U.S. Food and Drug Administration. (2020). FDA Drug Safety Communication: FDA reviewing the risk of blood clots in women taking certain birth control pills. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-reviewing-risk-blood-clots-women-taking-certain-birth-control-pills